Key result
PICM from active-fixation leadless pacemakers is linked to ~6.9-fold higher heart failure hospitalizations.
Why the study?
Pacing-induced cardiomyopathy (PICM) is a known complication of high right ventricular pacing burden with transvenous pacemakers, but its incidence and association with heart failure hospitalizations in patients receiving helix-based active-fixation leadless pacemakers were unknown.
What is the incidence of pacing-induced cardiomyopathy and its association with heart failure hospitalizations in patients implanted with active-fixation leadless pacemakers with ≥20% RV pacing burden?
Cohort (n=57)
Yes
What is the incidence of pacing-induced cardiomyopathy and its association with heart failure hospitalizations in patients implanted with active-fixation leadless pacemakers with ≥20% RV pacing burden?
Pacing-induced cardiomyopathy occurs in 10.5% of patients with active-fixation leadless pacemakers and high right ventricular pacing burden, significantly increasing the risk of heart failure hospitalization and underscoring the need for routine echocardiographic surveillance within the first year post-implant.
Answers are grounded in this paper and cite their sources.
Supports echocardiographic surveillance for PICM in leadless pacemaker recipients; hypothesis-generating pending prospective validation.
Introduction Pacing‐induced cardiomyopathy (PICM) is a known complication of high right ventricular (RV) pacing burden with transvenous pacemakers, but its incidence with active‐fixation leadless pacemakers (LPs) is unknown. This study's aim was to determine the incidence of PICM among patients implanted with LPs using helix‐based active fixation and assess its association with heart failure hospitalizations (HFH). Methods and Results This multi‐center retrospective cohort study included patients implanted with active‐fixation LPs between 2021 and 2025. Left ventricular ejection fraction (LVEF) measurements were obtained pre‐ and post‐implant. Inclusion criteria were: de novo pacemaker implant, ≥ 20% RV pacing burden, baseline LVEF of > 50%, and > 30 days of follow‐up. PICM was defined as a ≥ 10% reduction in LVEF from baseline to a value < 50%, with no other identifiable causes for left ventricular dysfunction. Patient demographics, comorbidities, procedural history, and baseline pacemaker, electrocardiographic, and echocardiographic data were compared between patients with and without PICM. Categorical variables were analyzed using the “N–1” Chi‐squared or Fisher's exact test and continuous variables with Welch's t ‐test. Cox proportional hazards models were used for univariate analysis of PICM and HFH. Among 164 patients implanted with active‐fixation LPs, 57 met inclusion criteria (mean age 78 ± 11 years). Dual‐chamber systems accounted for 47.4% of implants, and 96.5% of ventricular devices were placed in the low RV septum. Six patients (10.5%) developed PICM during 14.2 ± 10.9 months of follow‐up, with a mean time to onset of 7.5 ± 2.4 months. Baseline characteristics did not differ significantly between patients with and without PICM. At the time of diagnosis, those with PICM had a greater decline in LVEF (23% vs. 2%, p < 0.001). Although RV pacing burden was higher in PICM patients (88.8% vs. 76.6%), this difference was not statistically significant. PICM was a strong predictor of HFH (HR: 6.9, p = 0.007). Conclusion PICM occurred in 10.5% of patients receiving active‐fixation LPs with high ventricular pacing burden. Our findings highlight the importance of standardized follow‐up echocardiography within the first year post‐implant to improve surveillance and timely recognition of PICM.
No takes yet. Share an insight, caveat, or question.
Kopreski et al. (2026) conducted a cohort in Pacing-induced cardiomyopathy in patients with active-fixation leadless pacemakers (n=57). Active-fixation leadless pacemaker with ≥20% right ventricular pacing burden vs. Patients without pacing-induced cardiomyopathy was evaluated on Incidence of pacing-induced cardiomyopathy (≥10% reduction in LVEF from baseline to <50%) and association with heart failure hospitalization (HR 6.9, p=0.007). Active-fixation leadless pacemakers with ≥20% RV pacing resulted in a 10.5% incidence of pacing-induced cardiomyopathy, which strongly predicted heart failure hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: